Dopamine
Dopamine (dopamine) is a small molecule pharmaceutical. Dopamine was first approved as Dopamine hydrochloride on 1982-01-01. It is used to treat bradycardia, heart block, hypotension, kidney diseases, and low cardiac output amongst others in the USA. The pharmaceutical is active against D(3) dopamine receptor, D(4) dopamine receptor, D(1A) dopamine receptor, D(1B) dopamine receptor, and D(2) dopamine receptor. In addition, it is known to target glucose-dependent insulinotropic receptor, transient receptor potential cation channel subfamily M member 8, and transient receptor potential cation channel subfamily V member 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Dopamine (discontinued: Dopamine, Intropin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dopamine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER | Baxter | N-019615 RX | 1987-03-27 | 4 products, RLD, RS |
| DOPAMINE HYDROCHLORIDE | Hospira | N-018132 RX | 1982-01-01 | 4 products, RLD, RS |
| DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER | Hospira | N-018826 RX | 1983-09-30 | 3 products, RLD, RS |
Show 11 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dopamine hci | New Drug Application | 2024-02-22 |
| dopamine hci in 5% dextrose | New Drug Application | 2024-01-27 |
| dopamine hydrochloride | New Drug Application | 2025-02-17 |
| dopamine hydrochloride and dextrose | New Drug Application | 2020-11-11 |
| dopamine hydrochloride in dextrose | New Drug Application | 2024-11-25 |
| parcopa | 2007-11-05 | |
| sinemet | New Drug Application | 2024-10-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| kidney diseases | EFO_0003086 | D007674 | N08 |
| hypotension | EFO_0005251 | D007022 | I95 |
| shock | — | D012769 | R57.1 |
| low cardiac output | — | D002303 | — |
| bradycardia | — | D001919 | R00.1 |
| heart block | — | D006327 | I45.89 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01C: Cardiac stimulants excl. cardiac glycosides
— C01CA: Adrenergic and dopaminergic cardiac stimulants
— C01CA04: Dopamine
N: Nervous system drugs
— N04: Anti-parkinson drugs
— N04B: Dopaminergic agents
— N04BC: Dopamine agonists
HCPCS
Code | Description |
|---|---|
| J1265 | Injection, dopamine hcl, 40 mg |
Clinical
Clinical Trials
4987 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 1 | 2 | 3 | — | 6 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Movement disorders | D009069 | EFO_0004280 | G25 | 1 | 1 | — | — | — | 1 |
| Dyskinesias | D020820 | — | G24 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 8 | — | — | — | — | 8 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | — | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | — | — | — | — | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malignant carcinoid syndrome | D008303 | — | E34.0 | — | — | — | — | 1 | 1 |
| Serotonin syndrome | D020230 | EFO_1001842 | G90.81 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dopamine |
| INN | dopamine |
| Description | Dopamine is catechol in which the hydrogen at position 4 is substituted by a 2-aminoethyl group. It has a role as a cardiotonic drug, a beta-adrenergic agonist, a dopaminergic agent, a sympathomimetic agent, a human metabolite, an Escherichia coli metabolite and a mouse metabolite. It is a conjugate base of a dopaminium(1+). |
| Classification | Small molecule |
| Drug class | dopaminergics (butopamine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NCCc1ccc(O)c(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 51-61-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL59 |
| ChEBI ID | 18243 |
| PubChem CID | 681 |
| DrugBank | DB00988 |
| UNII ID | VTD58H1Z2X (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 190,248 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,442 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use